HR Execs on the Move

Xilio Therapeutics

www.xiliotx.com

 
Xilio is a Waltham, Massachusetts-based biopharmaceutical company focused on defeating cancer. The company`s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.xiliotx.com
  • 828 Winter Street
    Waltham, MA USA 02451
  • Phone: 617.833.1027

Executives

Name Title Contact Details
Christopher Frankenfield
Chief Financial Officer Profile
Erika Nicol
Vice President, Head of Human Resources Profile
Timothy Hunt
Chief Culture and Corporate Affairs Officer Profile
Salvatore Giovine
Chief Fnancial Officer Profile
Rene Russo
Chief Executive Officer Profile

Similar Companies

CalciMedica

CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.

BioServe

BioServe is a Beltsville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stuart Therapeutics

Stuart Therapeutics was established in 2017 for the development and commercialization of PolyCol, a versatile therapeutic platform that offers a unique tissue reparative approach to a variety of ophthalmic disease indications.

Aligos Therapeutics

Aligos Therapeutics is discovering and developing new classes of compounds that interact directly with disease causing molecules. These approaches are targeting viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins. The company is also pursuing novel therapeutic agents aimed at activation of the immune system to resolve diseases that cause significant morbidity and mortality.

Oncorus

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.